{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:01:54Z","timestamp":1790892114049,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.mcp.2024.101985","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T05:37:38Z","timestamp":1728365858000},"page":"101985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2"],"prefix":"10.1016","volume":"78","author":[{"given":"Behnaz","family":"Dolatabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Peymani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salehzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiavash","family":"Hushmandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.mcp.2024.101985_bib1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF\u2013ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.mcp.2024.101985_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"issue":"36","key":"10.1016\/j.mcp.2024.101985_bib3","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"Harder","year":"2009","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"6C","key":"10.1016\/j.mcp.2024.101985_bib4","first-page":"4535","article-title":"Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features","volume":"25","author":"Ansquer","year":"2005","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.mcp.2024.101985_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.971","article-title":"Evaluating HER2 amplification and overexpression in breast cancer","volume":"195","author":"Bartlett","year":"2001","journal-title":"J. Pathol.: A J.Pathol. Soc.G. B. Irel."},{"issue":"1","key":"10.1016\/j.mcp.2024.101985_bib6","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1038\/onc.2009.199","article-title":"Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer","volume":"28","author":"Hirsch","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.mcp.2024.101985_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bjc.2014.556","article-title":"Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer","volume":"112","author":"Lee","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcp.2024.101985_bib8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s12094-019-02213-9","article-title":"Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer","volume":"22","author":"Wang","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"8","key":"10.1016\/j.mcp.2024.101985_bib9","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","article-title":"Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases","volume":"30","author":"Medina","year":"2008","journal-title":"Clin. Therapeut."},{"issue":"3","key":"10.1016\/j.mcp.2024.101985_bib10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.radonc.2009.09.006","article-title":"Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf> MEK> ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK","volume":"93","author":"Sambade","year":"2009","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.mcp.2024.101985_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","article-title":"Lapatinib","author":"Voigtlaender","year":"2018","journal-title":"Small Mol.Oncol."},{"issue":"9","key":"10.1016\/j.mcp.2024.101985_bib12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/14737140.7.9.1183","article-title":"Lapatinib in the treatment of breast cancer","volume":"7","author":"Higa","year":"2007","journal-title":"Expet Rev. Anticancer Ther."},{"issue":"6","key":"10.1016\/j.mcp.2024.101985_bib13","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/bph.14816","article-title":"Natural compounds as potential adjuvants to cancer therapy: preclinical evidence","volume":"177","author":"Lin","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.mcp.2024.101985_bib14","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/antiox11091845","article-title":"The impact of oxidative stress and AKT pathway on cancer cell functions and its application to natural products","volume":"11","author":"Shiau","year":"2022","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.mcp.2024.101985_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1534735415610427","article-title":"Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: a systematic review","volume":"15","author":"Yasueda","year":"2016","journal-title":"Integr. Cancer Ther."},{"issue":"2","key":"10.1016\/j.mcp.2024.101985_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.urology.2006.12.003","article-title":"Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens\u2014evidence of schedule-dependent synergy","volume":"69","author":"McHugh","year":"2007","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.mcp.2024.101985_bib17","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mcp.2024.101985_bib18","volume":"vol. 5","author":"Law","year":"2016"},{"key":"10.1016\/j.mcp.2024.101985_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-015-0778-7","article-title":"Comparing the normalization methods for the differential analysis of Illumina high-throughput RNA-Seq data","volume":"16","author":"Li","year":"2015","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.mcp.2024.101985_bib20","article-title":"Maftools: Efficient analysis, visualization and summarization of MAF files from large-scale cohort based cancer studies","author":"Mayakonda","year":"2016","journal-title":"bioRxiv"},{"key":"10.1016\/j.mcp.2024.101985_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol."},{"issue":"6","key":"10.1016\/j.mcp.2024.101985_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.aller.2011.07.007","article-title":"Survival analysis and Cox regression","volume":"39","author":"Ben\u00edtez-Parejo","year":"2011","journal-title":"Allergol. Immunopathol."},{"issue":"7","key":"10.1016\/j.mcp.2024.101985_bib23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.mcp.2024.101985_bib24","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2024.101985_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.653491","article-title":"The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis","volume":"11","author":"Gan","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.mcp.2024.101985_bib26","article-title":"The frequency and clinical impact of HER2 alterations in lung adenocarcinoma","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.mcp.2024.101985_bib27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/0046-8177(93)90194-L","article-title":"Overexpression of HER2\/neu oncogene in human pancreatic carcinoma","volume":"24","author":"Yamanaka","year":"1993","journal-title":"Hum. Pathol."},{"issue":"9","key":"10.1016\/j.mcp.2024.101985_bib28","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.mcp.2024.101985_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.mcp.2024.101985_bib30","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.mcp.2024.101985_bib31","first-page":"71","article-title":"EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma","volume":"6","author":"Cossu-Rocca","year":"2016","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.mcp.2024.101985_bib32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1309\/H5UW6CPCWWC92241","article-title":"Significance of EGFR protein expression and gene amplification in non\u2013small cell lung carcinoma","volume":"125","author":"Dacic","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.mcp.2024.101985_bib33","article-title":"A comprehensive analysis of METTL1 to immunity and stemness in pan-cancer","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2024.101985_bib34","doi-asserted-by":"crossref","first-page":"9979707","DOI":"10.1155\/2021\/9979707","article-title":"LYAR promotes colorectal cancer progression by upregulating FSCN1 expression and fatty acid metabolism","volume":"2021","author":"Wu","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.mcp.2024.101985_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154009","article-title":"Identification of expression of CCND1-related lncRNAs in breast cancer","volume":"236","author":"Hussen","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.mcp.2024.101985_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1746-1596-8-138","article-title":"CyclinD1, a prominent prognostic marker for endometrial diseases","volume":"8","author":"Liang","year":"2013","journal-title":"Diagn. Pathol."},{"issue":"4","key":"10.1016\/j.mcp.2024.101985_bib37","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.3892\/ol.2017.6736","article-title":"Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer","volume":"14","author":"Shan","year":"2017","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.mcp.2024.101985_bib38","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1002\/cam4.2313","article-title":"Low level of Cyclin\u2010D1 correlates with worse prognosis of clear cell renal cell carcinoma patients","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med."}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850824000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850824000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T05:55:09Z","timestamp":1734328509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850824000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S0890850824000379"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2024.101985","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2024.101985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101985"}}